# CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)

> **NCT03289702** · PHASE3 · COMPLETED · sponsor: **Medy-Tox** · enrollment: 220 (actual)

## Conditions studied

- Muscle Spasticity

## Interventions

- **DRUG:** CORETOX®
- **DRUG:** BOTOX®

## Key facts

- **NCT ID:** NCT03289702
- **Lead sponsor:** Medy-Tox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-13
- **Primary completion:** 2018-06-30
- **Final completion:** 2018-11-09
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2021-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03289702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03289702, "CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03289702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*